Case Report: Safety and efficacy of blinatumomab in combination with donor lymphocyte infusion for the prophylaxis of relapse following allogeneic hematopoietic stem cell transplantation in a pediatric patient with acute lymphoblastic leukemia - Scorecard - MDSpire
Advertisement
Case Report: Safety and efficacy of blinatumomab in combination with donor lymphocyte infusion for the prophylaxis of relapse following allogeneic hematopoietic stem cell transplantation in a pediatric patient with acute lymphoblastic leukemia
Clinical Scorecard: Clinical Case Study: Evaluating the Safety and Effectiveness of Blinatumomab Combined with Donor Lymphocyte Infusion for Preventing Relapse After Allogeneic Hematopoietic Stem Cell Transplantation in a Child with Acute Lymphoblastic Leukemia
At a Glance
Category
Detail
Condition
Key Mechanisms
Blinatumomab combined with donor lymphocyte infusion (DLI) for relapse prevention post-HSCT.
Target Population
Care Setting
Key Highlights
Blinatumomab and DLI combination was well-tolerated in a pediatric patient.
The patient achieved negative MRD status after blinatumomab treatment.
Grade 1 cytokine release syndrome (CRS) occurred without severe adverse reactions.
Guideline-Based Recommendations
Diagnosis
Use of multiparameter flow cytometry (mFCM), quantitative PCR (qPCR), and next-generation sequencing (NGS) for MRD assessment.
Management
Sequential blinatumomab and prophylactic DLI for preventing post-transplant relapse.
Monitoring & Follow-up
Regular MRD monitoring to guide treatment decisions.
Risks
Post-transplant relapse associated with positive MRD status before HSCT.
Patient & Prescribing Data
Pediatric patients with high-risk ALL.
Blinatumomab has shown potential as maintenance therapy following HSCT.
